TargetDossier — plain-English protein briefs for biotech investors and program leads
A briefing tool that turns protein function, dynamics, and structure predictions into a short, non-technical brief so biotech investors, BD teams, and non-PhD program leads can keep up with the science.
Biotech investors, business-development leads, and program managers without deep protein-chemistry backgrounds
- Auto-generated 1-page brief on any protein target with current evidence and uncertainty
- Weekly digest of newly characterized targets in your portfolio or watchlist
- Plain-English glossary that flags when a prediction is high versus low confidence
- Side-by-side comparison of competing drug-target candidates on the same protein
Protein-AI breakthroughs are moving faster than non-scientist stakeholders can absorb; a translation layer that surfaces the 'so what' for each target is missing.
Multiple established platforms serve biotech investors/BD with target intelligence (biotech.today, InBioHealth, Imagine biotech.ai) and a 2026 guide lists 25 such platforms, confirming real demand; MIT research also flags growing need to translate protein model outputs into plain English.The Biotech Investor Tools Stack: 25 Platforms Powering Life Science Investing 2026 ↗Researchers glimpse the inner workings of protein language models ↗
Crowded adjacencies — InBioHealth sells 'Buy Now' target reports, Imagine biotech.ai offers 'easily digestible reports for biotech investors,' and biotech.today tracks drug-discovery AI — but none are explicitly a per-protein plain-English brief layer aimed at non-PhDs, leaving a narrow translation niche.InBioHealth - AI-Powered Biotech Stock Intelligence ↗Imagine biotech.ai | Scientific Due Diligence ↗
Existing players monetize via paid reports and pro subscriptions (InBioHealth 'Buy Now' reports, pro biotech intelligence tiers), and investors routinely pay for diligence — but no public pricing found for per-protein briefs, leaving willingness-to-pay for this specific SKU unverified.InBioHealth - AI-Powered Biotech Stock Intelligence ↗The Biotech Investor Tools Stack: 25 Platforms Powering Life Science Investing 2026 ↗
Protein AI is accelerating rapidly (AlphaFold 3, diffusion protein design, ProtMMLM-era PLMs) and the gap between scientific output and non-scientist comprehension is widening — Nature and CSAIL both describe a translation problem that will grow, not shrink.I told AI to make me a protein. Here's what it came up with - Nature ↗From AlphaFold to Diffusion: How AI Is Rewriting the Blueprint of Life ↗
MIT/CSAIL already demonstrated Claude-based sparse-autoencoder translation of protein features into plain English, and AlphaFold/UniProt provide the underlying data — building a brief is largely an LLM-prompting + retrieval problem, though scientific accuracy and hallucination risk are real concerns.Researchers glimpse the inner workings of protein language models ↗